Glycotope GmbH (Glycotope) and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) have recently entered into a collaborative agreement to integrate Glycotope's antibodies with Evotec's immune cell engager platform for the development of next-generation immune cell engaging bispecifics.

While first-generation immune cell engager (ICE) bispecifics have revolutionized liquid tumor therapy, their effectiveness in treating solid tumors has been limited, largely due to the heightened risk of off-target toxicity. The unique ability of Glycotope's antibodies to target specific tumor-associated protein/carbohydrate combined glyco-epitopes (GlycoTargets) positions them as promising candidates when combined with the Evotec platform, offering the potential to create next-generation ICE bispecifics tailored for solid tumor indications.

Dr. Cord Dohrmann, Chief Scientific Officer of Evotec SE, expressed optimism regarding Glycotope's antibodies, citing their applicability to various tumor indications and strong tumor selectivity, making them ideal targeting agents for their immune cell engager platform.

Henner Kollenberg, CEO of Glycotope, conveyed excitement about the collaboration, emphasizing the exploration of next-generation immune cell engaging bispecifics for diverse indications, including solid tumors.

Patrik Kehler, CSO of Glycotope, underscored the strategic significance of the partnership, highlighting the expanded potential application areas for their antibodies. The collaboration with Evotec, renowned for creating top-tier bispecifics, presents a compelling opportunity to explore innovative treatments for patients across a spectrum of indications.

 

Source: globenewswire.com

Report Abuse